There is currently a national shortage of STI collection kits for APTIMA testing. This shortage will affect APTIMA testing for Chlamydia, Gonococcus, Trichomonas and Mycoplasma Genitalium (MGen). Spectrum Health Laboratories does offer alternative collection devices and testing for Chlamydia, Gonococcus and Trichomonas.
At this time when Influenza prevalence is not widespread in the community, please order “Influenza A/B PCR” [LAB3255] when testing is needed. This applies to patients at all Grand Rapids and regional hospitals, and also system wide ambulatory patients.
Effective March 4th, 2020, Thrombin Time will change from a sendout reference test performed by Mayo Clinic Laboratories to an in-house test performed by Spectrum Health Regional Laboratory. This test will be performed in the Coagulation Laboratory and will include a new reference range (please see link in Test Information below).
Thrombin Time is suitable for monitoring fibrinolysis therapy, screening for disorders of fibrin formation and in cases of suspected fibrinogen deficiency states. It is also useful for the differentiation between a heparin induced prolongation of the thrombin time and fibrin formation disorders.
For questions around this test, please contact the Coagulation Department at 616-267-2740.
The most conclusive evidence for using thyroid peroxidase antibody (TPO) is predictive in nature when evaluating possible subclinical hypothyroidism. If this test is positive, hypothyroidism occurs at a rate of 4.3% per year versus 2.6% per year when the antibody is negative. While this scenario does not cover all clinical indications for ordering TPO, there is no definitive evidence that repeat TPO testing provides additional information.1
Based on this information the ordering of TPO within Spectrum Health is being modified. If the test is ordered more than once on a patient, a screen will appear in EPIC indicating the following: “This test should typically only be resulted once per lifetime. The duplicate checking indicates that this patient has already had this testing performed. Please see chart review for results.” This is not a “hard stop” but providers will need to click “Continue” to proceed with the order.
Effective December 11th, 2019, Spectrum Health Regional Laboratory’s Immunochemistry laboratory will be upgrading the following tests from the Immunoassay Vidas platform to the Multiplex flow immunoassay Bioplex 2200 platform.
In December, serum and urine protein electrophoresis testing will be simplified and standardized. The only testing available will be:
In addition, on December 5, 2019, a new panel will be added which reflects expert recommendations for first line testing for monoclonal gammopathy, including plasma cell myeloma and most cases of amyloidosis, called “Monoclonal Gammopathy Screen”
To better align with our Allergy Specialists and reduce confusion and costs to patients, we have simplified and standardized our Allergy Panel offerings. These new panels will be available to order beginning Thursday, October 24, 2019. Also effective on this date, several of our old panels will be discontinued.